Results 171 to 180 of about 82,211 (293)

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

open access: yesClinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Neoadjuvant disitamab vedotin combined with camrelizumab and S‐1 achieved high pathological response rates with manageable safety in resectable HER2‐overexpressing gastric and gastroesophageal junction cancer. Longitudinal circulating tumour DNA methylation profiling enabled dynamic monitoring of molecular response during treatment.
Longgang Wang   +10 more
wiley   +1 more source

Frequency of thiopurine methyltransferase variants and exploratory predictors of azathioprine-induced leukopenia in Saudi patients with inflammatory bowel disease. [PDF]

open access: yesSaudi J Gastroenterol
Meeralam YK   +7 more
europepmc   +1 more source

Liver Transplantation Outcomes in Crigler‐Najjar Syndrome in Iran: A Single‐Center Retrospective Cohort Study Over 20 Years

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Crigler‐Najjar Syndrome (CNS) is a rare autosomal recessive disorder caused by uridine diphosphate glucuronosyltransferase (UGT1A1) deficiency, leading to unconjugated hyperbilirubinemia. Without treatment, patients are at high risk of kernicterus and irreversible neurological damage.
Sajad Teimoury   +6 more
wiley   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2429-2439, 1 May 2026.
What's new? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu   +14 more
wiley   +1 more source

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2219-2228, 1 May 2026.
What's new? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma   +11 more
wiley   +1 more source

In Regard to Huang et al. [PDF]

open access: yesAdv Radiat Oncol
Sengul I, Sengul D.
europepmc   +1 more source

Acquired Angioedema Associated With Systemic Lupus Erythematosus Presenting as Acute Abdomen: A Case Report

open access: yesJournal of General and Family Medicine, Volume 27, Issue 3, May 2026.
ABSTRACT Acquired angioedema (AAE) due to C1 inhibitor deficiency can present as acute abdomen. A 24‐year‐old woman developed severe abdominal pain and bowel wall edema initially suggestive of hereditary angioedema, but genetic testing excluded it. She later manifested fever, arthritis, rash, and serological abnormalities consistent with systemic lupus
Seiji Shiota   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy